Intellia Therapeutics, Inc. (0JBU.L)
0JBU.L Stock Price Chart
Explore Intellia Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze 0JBU.L price movements and trends.
0JBU.L Company Profile
Discover essential business fundamentals and corporate details for Intellia Therapeutics, Inc. (0JBU.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jan 2018
Employees
403.00
Website
https://www.intelliatx.comCEO
John M. Leonard
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
0JBU.L Financial Timeline
Browse a chronological timeline of Intellia Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 5 Nov 2025
Upcoming earnings on 6 Aug 2025
Revenue estimate is $12.26M.
Earnings released on 8 May 2025
EPS came in at -$1.10 surpassing the estimated -$1.28 by +14.00%, while revenue for the quarter reached $16.63M, beating expectations by +39.34%.
Earnings released on 27 Feb 2025
EPS came in at -$1.27 surpassing the estimated -$1.33 by +4.90%, while revenue for the quarter reached $12.87M, beating expectations by +58.94%.
Earnings released on 7 Nov 2024
EPS came in at -$1.34 surpassing the estimated -$1.39 by +3.61%, while revenue for the quarter reached $9.11M, beating expectations by +2.32%.
Earnings released on 8 Aug 2024
EPS came in at -$1.52 falling short of the estimated -$1.22 by -24.56%, while revenue for the quarter reached $6.96M, missing expectations by -64.64%.
Earnings released on 9 May 2024
EPS came in at -$1.12 surpassing the estimated -$1.37 by +17.66%, while revenue for the quarter reached $28.94M, beating expectations by +157.37%.
Earnings released on 12 Mar 2024
EPS came in at -$1.46 falling short of the estimated -$1.44 by -1.57%, while revenue for the quarter reached -$1.92M, missing expectations by -115.04%.
Earnings released on 9 Nov 2023
EPS came in at -$1.38 surpassing the estimated -$1.50 by +7.99%, while revenue for the quarter reached $11.99M, missing expectations by -8.10%.
Earnings released on 3 Aug 2023
EPS came in at -$1.40 falling short of the estimated -$1.32 by -6.18%, while revenue for the quarter reached $13.59M, beating expectations by +12.55%.
Earnings released on 4 May 2023
EPS came in at -$1.17 surpassing the estimated -$1.40 by +16.05%, while revenue for the quarter reached $12.61M, beating expectations by +6.53%.
Earnings released on 23 Feb 2023
EPS came in at -$1.40 falling short of the estimated -$1.38 by -1.27%, while revenue for the quarter reached $13.57M, beating expectations by +19.76%.
Earnings released on 30 Sept 2022
EPS came in at -$1.49 falling short of the estimated -$1.29 by -15.83%, while revenue for the quarter reached $13.27M, beating expectations by +11.61%.
Earnings released on 30 Jun 2022
EPS came in at -$1.33 falling short of the estimated -$1.30 by -1.83%, while revenue for the quarter reached $14.03M, beating expectations by +49.00%.
Earnings released on 31 Mar 2022
EPS came in at -$1.96 falling short of the estimated -$1.11 by -77.17%, while revenue for the quarter reached $11.25M, beating expectations by +31.75%.
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
Earnings released on 31 Dec 2021
EPS came in at -$1.09, while revenue for the quarter reached $12.85M.
Earnings released on 30 Sept 2021
EPS came in at -$0.97 falling short of the estimated -$0.95 by -2.43%, while revenue for the quarter reached $7.20M, missing expectations by -12.81%.
Earnings released on 30 Jun 2021
EPS came in at -$1.01, while revenue for the quarter reached $6.55M.
Earnings released on 31 Mar 2021
EPS came in at -$0.69, while revenue for the quarter reached $6.45M.
Earnings released on 31 Dec 2020
EPS came in at -$0.69, while revenue for the quarter reached $6.60M.
Earnings released on 30 Sept 2020
EPS came in at -$0.47, while revenue for the quarter reached $22.22M.
0JBU.L Stock Performance
Access detailed 0JBU.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.